中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

46 records (took 0.02 seconds)

    Production of interferon
    31.
    发明授权
    Production of interferon 失效

    公开(公告)号：US5468607A

    公开(公告)日：1995-11-21

    申请号：US208925

    申请日：1980-11-20

    Applicant: Michel Revel ,  Pierre Tiollais

    Inventor： Michel Revel ,  Pierre Tiollais

    IPC: C12N15/09 ,  C07H21/02 ,  C07H21/04 ,  C07K14/54 ,  C07K14/565 ,  C12N15/00 ,  C12N15/22 ,  C12P19/34 ,  C12P21/00 ,  C12P21/02 ,  C12R1/19 ,  C12R1/91 ,  C12N15/70 ,  C12Q1/68

    CPC classification number: C07K14/5412 ,  C07K14/565

    Abstract: The present invention relates to a process to isolate genetic material (DNA) containing the nucleotide sequence coding for interferon in human fibroblastic cells which comprises cultivating cells producing interferon when exposed to an inducer of interferon, exposing same to such inducer, extracting messenger RNA from said induced cells, purifying the interferon messenger RNA, transcribing the messenger RNA into DNA and cloning the DNA in a suitable vector. Preferred cells are human diploid foreskin cells. The invention further relates to a process for engineering a bacterial strain to produce interferon polypeptide which comprises introducing a cloned interferon DNA into a suitable vector-carrier. A preferred vector-carrier is E. coli. The invention also relates to the mRNA of human interferon in highly purified form, to the mRNA of human interferon in .beta.1 highly purified form, to the mRNA of human interferon in .beta.2 highly purified form, to the DNA coding for a polypeptide having interferon activity, insertable in a vector, such as plasmid pBR322, and also to human interferon .beta.1 in highly purified form, and human interferon .beta.2 in highly purified form.

    Antiviral compositions
    33.
    发明授权
    Antiviral compositions 失效
    抗病毒组合物

    公开(公告)号：US4898891A

    公开(公告)日：1990-02-06

    申请号：US82700

    申请日：1987-08-07

    Applicant: David Lavie ,  Michel Revel ,  Dalia Rotman ,  Vincent V. Velde

    Inventor： David Lavie ,  Michel Revel ,  Dalia Rotman ,  Vincent V. Velde

    IPC: A61K31/12 ,  C07C50/36

    CPC classification number: A61K31/12 ,  C07C50/36

    Abstract: The invention relates to antiviral compositions of matter containing as active ingredient hypericin or pseudohypericin. The novel compositions are of special use in the treatment of, and alleviation of symptoms of various diseases caused by viruses such as vesicular stomatitis, influenza, herpes simplex, HSV-1 and HSV-2. The mode of activity seems to be by inhibition of RNA synthesis and interfering with virus replication. The pharmaceutical compositions can be applied by a variety of routes. Topical applications have proved to be effective against a variety of viral afflictions.

    Abstract translation: 本发明涉及包含作为活性成分金丝桃素或假倍孕素的物质的抗病毒组合物。 该新型组合物特别用于治疗和缓解由诸如水泡性口炎，流感，单纯疱疹，HSV-1和HSV-2等病毒引起的各种疾病的症状。 活动方式似乎是通过抑制RNA合成和干扰病毒复制。 药物组合物可以通过各种途径施用。 已证明局部应用对各种病毒性疾病有效。

    (2'-5')Oligo-isoadenylate pharmaceutical compositions and method of use
    35.
    发明授权
    (2'-5')Oligo-isoadenylate pharmaceutical compositions and method of use 失效
    （2'-5'）寡烯 - 异腺苷酸药物组合物和使用方法

    公开(公告)号：US4378352A

    公开(公告)日：1983-03-29

    申请号：US195057

    申请日：1980-10-08

    Applicant: Adi Kimchi ,  Michel Revel ,  Sara Rappoport ,  Yehuda Lapidot

    Inventor： Adi Kimchi ,  Michel Revel ,  Sara Rappoport ,  Yehuda Lapidot

    IPC: C07H21/00 ,  C12P19/34

    CPC classification number: C07H21/00 ,  Y10S514/885

    Abstract: The invention relates to a novel process for the production of (2'-5')A(pA).sub.n pA chains wherein n is an integer of from 1 to 6, which comprises polymerizing adenosine (2'-3') monophosphate to obtain a mixture of 2'-5'- and 3'-5'-polyadenylic acid, treating the mixture with ribonuclease P.sub.1 to cleave selectively the 3'-5'-bonds so as to retain the 2'-5'-polymeric moieties with a terminal 5'-phosphate moiety and removing the terminal phosphate groups by means of alkaline phosphatase. The mixture may be purified by separation on an anionic ion exchanger and collecting the individual fractions. The invention further relates to pharmaceutical compositions for inhibiting the immune response of mammals which comprise as active ingredient a (2'-5')oligo-isoadenylate defined above. The preferred compositions are those with a preponderance of the trimer.

    Abstract translation: 本发明涉及一种制备（2'-5'）A（pA）npA链的新方法，其中n是1至6的整数，其包括使腺苷（2'-3'）一磷酸聚合以获得 2'-5'-和3'-5'-聚腺苷酸的混合物，用核糖核酸酶P1处理该混合物以选择性地切割3'-5'-键，从而将2'-5'-聚合物部分与 末端5'-磷酸部分，并通过碱性磷酸酶除去末端磷酸酯基。 可以通过在阴离子离子交换剂上分离来纯化混合物并收集各个级分。 本发明还涉及用于抑制哺乳动物的免疫应答的药物组合物，其包含作为活性成分的上述限定的（2'-5'）寡聚异己烯酸酯。 优选的组合物是具有三聚体优势的组合物。

Patent Agency Ranking